GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » Cyclically Adjusted FCF per Share

Regulus Therapeutics (STU:7RG0) Cyclically Adjusted FCF per Share : €-59.20 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regulus Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Regulus Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.287. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-59.20 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 60.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Regulus Therapeutics was 60.10% per year. The lowest was 60.10% per year. And the median was 60.10% per year.

As of today (2024-05-16), Regulus Therapeutics's current stock price is €1.86. Regulus Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-59.20. Regulus Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Regulus Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Regulus Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Cyclically Adjusted FCF per Share Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -805.64 -858.37 -70.64 -59.71

Regulus Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.05 -63.74 -67.37 -59.71 -59.20

Competitive Comparison of Regulus Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Regulus Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Regulus Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regulus Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.287/129.4194*129.4194
=-0.287

Current CPI (Mar. 2024) = 129.4194.

Regulus Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -21.137 100.560 -27.203
201409 -19.110 100.428 -24.627
201412 -24.258 99.070 -31.689
201503 -25.472 99.621 -33.091
201506 -20.810 100.684 -26.749
201509 -25.277 100.392 -32.586
201512 -36.890 99.792 -47.842
201603 -19.098 100.470 -24.601
201606 -34.870 101.688 -44.379
201609 -32.386 101.861 -41.148
201612 -32.844 101.863 -41.729
201703 -39.844 102.862 -50.131
201706 -34.781 103.349 -43.555
201709 -13.136 104.136 -16.325
201712 -10.878 104.011 -13.535
201803 -14.594 105.290 -17.939
201806 -12.026 106.317 -14.639
201809 -11.274 106.507 -13.699
201812 -4.008 105.998 -4.894
201903 -3.779 107.251 -4.560
201906 -3.014 108.070 -3.609
201909 -2.056 108.329 -2.456
201912 -2.134 108.420 -2.547
202003 -2.258 108.902 -2.683
202006 -1.557 108.767 -1.853
202009 -1.001 109.815 -1.180
202012 0.548 109.897 0.645
202103 -0.679 111.754 -0.786
202106 -0.554 114.631 -0.625
202109 -0.546 115.734 -0.611
202112 -0.650 117.630 -0.715
202203 -0.403 121.301 -0.430
202206 -0.411 125.017 -0.425
202209 -0.454 125.227 -0.469
202212 -0.354 125.222 -0.366
202303 -0.450 127.348 -0.457
202306 -0.302 128.729 -0.304
202309 -0.325 129.860 -0.324
202312 -0.281 129.419 -0.281
202403 -0.287 129.419 -0.287

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Regulus Therapeutics  (STU:7RG0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Regulus Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics (STU:7RG0) Business Description

Industry
Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Regulus Therapeutics (STU:7RG0) Headlines

No Headlines